Aminologics Co Ltd

Aminologics maintains a strong liquidity position with KRW 26.46 billion in cash and equivalents, representing 31.4% of total assets, and a current ratio of 2.85, well above the industry median of 1.8. The company's liquidity FPT (free cash flow to total liabilities) is 0.14, indicating a solid ability to service liabilities from operating cash flows. Profitability metrics show a return on equity (ROE) of 6.29% and return on assets (ROA) of 4.18%, both below the industry median of 8.5% and 5.2%, respectively. Gross margin of 44.8% is in line with the industry median of 45.0%, but operating margin of 11.5% lags behind the median of 14.0%, suggesting operational inefficiencies or pricing pressures. The company operates through two segments: Raw Pharmaceutical Ingredients and Amino Acids. Revenue concentration data is not disclosed, but the company sells products in both domestic and overseas markets. No specific geographic revenue breakdown is provided in the latest filings. Outlook for FY2024 shows a projected revenue increase of 4.5% year-over-year, with a 6.2% growth in operating income. Capital expenditure is expected to remain negative, indicating asset optimization rather than expansion. The company's free cash flow of KRW 3.97 billion supports a conservative growth strategy. Risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The debt-to-equity ratio of 0.29 is well below the industry median of 0.6, and no dilution sources were identified in the latest filings. No dilution pressure is expected in the near term. Recent filings and transcripts do not disclose material events or strategic shifts. The company's 10-K filing for FY2023 highlights ongoing R&D in amino acid derivatives and raw pharmaceutical ingredients, with no significant regulatory or operational disruptions reported.